Resources
About Us
Home Report
Store
Tuberculosis Diagnostics Market
Tuberculosis Diagnostics Market Size, Share, Forecast, & Trends Analysis by Test Type (Mantoux, IGRA, Radiography [X-ray, CT] Molecular [NAAT, WGS, Rapid] Culture, Sputum Smear), End User (Hospital, Diagnostic Lab), Infection Stage – Global Forecast to 2031
Report ID:MRHC - 1041202 Pages: 260 May-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 72 HoursThe Tuberculosis Diagnostics Market was valued at $2.41 billion in 2023. This market is expected to reach $3.56 billion by 2031, from an estimated $2.54 billion in 2024, at a CAGR of 5% during the forecast period 2024-2031.
Tuberculosis Diagnostics Market Size & Forecast
The growth of this market can be attributed to the rising prevalence of tuberculosis (TB) in low—and middle-income countries, the emergence of drug-resistant strains, and favorable initiatives for TB diagnosis and treatment. Moreover, initiatives by governments and organizations to raise awareness regarding tuberculosis are expected to generate growth opportunities for the players operating in the tuberculosis diagnostics market.
Tuberculosis Diagnostics Market Growth Drivers
Rising Prevalence of Tuberculosis in Low- and Middle-Income Countries
Around a quarter of the global population is estimated to have been infected with TB bacteria. According to the World Health Organization (WHO), in 2022, around 1.3 million people succumbed to tuberculosis (TB) globally. Moreover, 10.6 million people fell ill from TB in 2022 globally. However, the middle- and low-income countries have the highest TB burden, accounting for 80% of total deaths caused by TB. In 2022, the largest number of new TB cases occurred in WHO’s Southeast Asian Region, accounting for 46%, the African Region, accounting for 23%, and the Western Pacific region, accounting for 18%. Around 87% of new TB cases occurred in the 30 high TB-burden countries, with more than two-thirds of the global total in Bangladesh, China, the Democratic Republic of the Congo, India, Indonesia, Nigeria, Pakistan, and the Philippines.
Reducing the TB burden in low- and middle-income countries is expected to lead to the adoption of diagnostic tests for early diagnosis and treatment, driving market growth.
Click here to: Get Free Sample Pages of this Report
Tuberculosis Diagnostics Market Trends
Growing Biomarker Research for Tuberculosis
Biomarker research for tuberculosis (TB) is growing, and there is a wide range of biomarkers that can be used to detect the presence of the disease. These biomarkers can be related to either the pathogen or the host and include:
Pathogen Biomarkers: Mycobacterium tuberculosis (Mtb) products can be detected in blood, urine, or sputum. Mtb DNA can be detected in the blood and urine of pulmonary TB patients with greater sensitivity than Mtb culture.
Host Biomarkers: These include antibody response, cytokine response, and blood-based gene expression signatures. Antibodies are often used because they are inexpensive and easy to test. Cytokine response involves measuring the release of Interferon‐Gamma (IFN‐γ) after blood stimulation with Mtb‐specific antigens.
The growing research on TB biomarkers is expected to lead to the discovery of novel biomarkers, which will aid in the development of better and more precise tests for TB diagnosis.
Emergence of Point-of-Care (PoC) Testing
Point-of-care (POC) diagnostic tests for tuberculosis (TB) are portable, user-friendly tests that can be performed near the patient without the need for specialized training or extensive laboratory infrastructure. POC tests can help to: Detect TB early, Initiate treatment immediately, Reduce TB transmission, and Improve patient outcomes. These tests are beneficial, especially in the camps and temporary medical centers established by global organizations such as the United Nations and WHO. These medical centers are established at places of TB outbreaks or underdeveloped regions where governments are unable to carry out effective TB management. Thus, the emergence of PoC tests is expected to positively impact the growth of the tuberculosis diagnostics market.
Tuberculosis Diagnostics Market Opportunity
Initiatives by Governments and Organizations to Raise Awareness regarding Tuberculosis
Due to the huge burden of TB globally, several initiatives are being undertaken to raise awareness about tuberculosis. For instance:
-
In September 2023, the United Nations (UN) held a second high-level meeting concerning TB. Highlights of the meeting include improving access to TB services, accelerating research, aiming to reduce vulnerability, and mobilizing resources for effective TB control. This is aimed at a global effort to combat tuberculosis.
- In 2022, the President of India launched Pradhan Mantri TB Mukt Bharat Abhiyaan, a campaign to eliminate TB from the country by 2025.
- In 2022, the United States Agency for International Development (USAID) released its eight-year Global Tuberculosis (TB) Strategy 2023-2030, which aims to achieve a 35% decline in TB incidence and a 52% reduction in TB mortality compared to 2019 levels. Additionally, the goals entail diagnosing and initiating treatment for 90% of new TB and drug-resistant TB cases, maintaining a 90% treatment success rate for both drug-sensitive and drug-resistant TB, and administering TB preventive treatment to 30 million individuals.
Tuberculosis Diagnostics Market Analysis: Key Findings
By Test Type: In 2024, the Skin Test/Mantoux Segment to Dominate the Tuberculosis Diagnostics Market
Based on test type, the market is segmented into skin test/Mantoux, radiographic tests, molecular tests, sputum smear microscopy, culture & drug resistance tests, and other test types. In 2024, the skin test segment is expected to account for the largest share of 38.2% of the tuberculosis diagnostics market. The large market share of this segment is attributed to the ease and simplicity of the test, cost-effectiveness, and the ability to test for latent infections.
However, the molecular tests segment is projected to register the highest growth rate of 5.8% during the forecast period of 2024–2031. The segment’s growth is driven by the high efficiency and accuracy of molecular tests, technological advancements in molecular diagnostic technology, increasing availability of molecular tests for TB, and initiatives by the companies to introduce rapid molecular diagnostic tests for TB & drug resistance. Moreover, the new guidelines by public organizations such as the WHO regarding molecular TB tests further drive the segment’s growth. For instance, in March 2024, the WHO published recommendations on the use of a new class of diagnostic technologies: targeted next-generation sequencing (NGS) tests for the diagnosis of drug-resistant tuberculosis (TB).
By Infection Stage: In 2024, the Active Segment to Dominate the Tuberculosis Diagnostics Market
Based on infection stage, the tuberculosis diagnostics market is segmented into active and latent. In 2024, the active segment is expected to account for the larger share of 52.0% of the tuberculosis diagnostics market. The large share of the segment is attributed to the large burden of active cases globally, rising awareness regarding tuberculosis, and favorable initiatives for TB diagnosis and treatment. For instance, on 24th March 2023, the Stop TB Partnership hosted by the United Nations Office for Project Services (UNOPS) released a toolkit called “Yes! We Can End TB.” This toolkit was launched to bring attention to TB and the efforts to end TB by the year 2030.
Similarly, the active segment is expected to register the highest CAGR during the forecast period of 2024-2031. This segment’s growth is attributed to the increasing prevalence of tuberculosis in low- and middle-income countries, aims and goals set by the governments and public organizations to manage the TB burden, and growing instances of TB outbreaks. For instance, in May 2024, the City Council in Long Beach, California (U.S.) declared a health emergency due to the outbreak of TB in the city. Moreover, as of April 29, 2024, 14 cases were found infected, and around 170 people were exposed.
By End User: In 2024, the Diagnostic Laboratories Segment to Dominate the Tuberculosis Diagnostics Market
Based on end user, the tuberculosis diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, academic & research institutes, and other end users. In 2024, the diagnostic laboratories segment is expected to account for the largest share of the market. The availability of a wide menu of tests, rising awareness regarding TB, and increased identification of TB cases due to prompt testing contribute to the segment’s large share.
The diagnostic laboratories segment is also expected to register the highest CAGR during the forecast period. This segment’s growth is attributed to favorable initiatives to raise awareness regarding TB and the launch of new diagnostic tests for TB and drug resistance. For instance, in January 2023, Molbio Diagnostics Pvt. Ltd. (India) launched the Treunat MTB-INH to test the presence of isoniazid resistance in Mycobacterium tuberculosis bacteria.
Geographical Analysis
In 2024, North America is expected to account for the largest share of 34.1% of the tuberculosis diagnostics market. Among the U.S. and Canada, in 2024, the U.S. is expected to account for the largest share of the tuberculosis diagnostics market in North America. The region’s large share is attributed to the high awareness regarding TB, routine TB testing for latent infections by the people traveling to the TB burdened countries, and adoption of advanced diagnostic methods.
However, Asia-Pacific is slated to register the highest CAGR of 6.6% during the forecast period. Among the countries in the Asia-Pacific region, India and China are expected to register the highest CAGR during the forecast period. This growth is attributed to favorable government initiatives to strengthen the TB diagnostic infrastructure in the countries, aiming towards the eradication of TB and increasing awareness regarding TB.
Tuberculosis Diagnostics Market: Key Companies
The report offers a competitive analysis based on an extensive assessment of the leading players’ product portfolios, geographic presence, and key growth strategies adopted in the last 3–4 years. The key players operating in the tuberculosis diagnostics market are F. Hoffmann-La Roche Ltd. (Switzerland), Becton, Dickinson and Company (U.S.), Abbott Laboratories, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), QIAGEN GmbH (Germany), Hologic, Inc. (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), Oxford Immunotec Ltd. (U.K.), Hain Lifescience GmbH (Germany), and Creative Diagnostics (U.S.).
Mental Health Apps Industry Overview: Latest Developments from Key Industry Players
-
In November 2023, Revvity, Inc. (U.S.) launched its T-SPOT.TB test for latent TB screening in India.
-
In October 2023, the Serum Institute of India launched a point-of-care skin test for detecting latent tuberculosis infections.
- In April 2023, Boditech Med Inc. (South Korea) entered into an agreement with the Menarini Group (Italy). Under this agreement, Menarini will be the exclusive distributor of Boditech’s AFIAS-10 Single Test Immuno-Assay System, including IGRA-Tuberculosis, in 34 European countries.
Tuberculosis Diagnostics Market Research Summary:
|
Particular |
Details |
|
Page No |
260 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2023 |
|
CAGR |
5% |
|
Market Size (Value) |
$3.56 billion by 2031 |
|
Segments Covered |
By Test type
By Infection Stage
By End User
|
|
Countries Covered |
North America (U.S., Canada), Europe (Germany, France, U.K., Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Indonesia, Thailand, Philippines, South Korea, Australia, Singapore, Rest of APAC), Latin America, Middle East, and Africa (South Africa, Nigeria, Kenya, Rest of Africa) |
|
Key Companies |
F. Hoffmann-La Roche Ltd. (Switzerland), Becton, Dickinson and Company (U.S.), Abbott Laboratories, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), QIAGEN GmbH (Germany), Hologic, Inc. (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), Oxford Immunotec Ltd. (U.K.), Hain Lifescience GmbH (Germany), Creative Diagnostics (U.S.) |
Key questions answered in the tuberculosis diagnostics market report:
The tuberculosis diagnostics market covers the sizes & forecasts by test type, infection stage, and end user. This report studies the market by analyzing the value of various segments and sub-segments at regional and country levels.
The tuberculosis diagnostics market is projected to reach $3.56 billion by 2031, at a CAGR of 5% during the forecast period.
In 2024, the skin test segment is expected to account for the largest share of the tuberculosis diagnostics market.
The growth of this market can be attributed to the rising prevalence of tuberculosis in low—and middle-income countries, the emergence of drug-resistant strains, and favorable initiatives for TB diagnosis and treatment. Moreover, initiatives by governments and organizations to raise awareness regarding tuberculosis are expected to generate growth opportunities for the players operating in the tuberculosis diagnostics market.
The key players operating in the tuberculosis diagnostics market are F. Hoffmann-La Roche Ltd. (Switzerland), Becton, Dickinson and Company (U.S.), Abbott Laboratories, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), QIAGEN GmbH (Germany), Hologic, Inc. (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), Oxford Immunotec Ltd. (U.K.), Hain Lifescience GmbH (Germany), and Creative Diagnostics (U.S.).
India and China are projected to offer significant growth opportunities for vendors in this market due to favorable government initiatives to strengthen the TB diagnostic infrastructure in these countries, which aim to eradicate TB and increase awareness regarding it.
1. Overview
1.1. Market Definition and Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of The Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions For the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Market Dynamics
4.2.1.1. Drivers
4.2.1.1.1. Rising Prevalence of Tuberculosis in LMICs
4.2.1.1.2. Emergence of Drug Resistant Strains
4.2.1.1.3. Favorable Initiatives for TB Diagnosis and Treatment
4.2.1.2. Restraints
4.2.1.2.1. Problems Associated with TB Testing
4.2.1.2.1.1. False Positives
4.2.1.2.1.2. Delays in Test Results Due to Delay in Immune Reaction
4.2.1.2.1.3. Poor Sensitivity of Tests
4.2.1.3. Opportunities
4.2.1.3.1. Initiatives by Governments and Organizations to Raise Awareness Regarding Tuberculosis
4.2.1.4. Challenges
4.2.1.4.1. Stigma Associated Regarding TB Patients
4.3. Trends
4.3.1. Emergence of Point-of-Care Testing
4.3.2. Biomarker Research for TB
4.4. Regulatory Analysis
4.5. Porters Five Forces Analysis
4.6. Product Pipeline Analysis
4.7. Fundings & Investment Analysis
5. Tuberculosis Diagnostics Market Assessment—by Test Type
5.1. Overview
5.2. Skin Test/Mantoux
5.3. Interferon Gamma Release Assay
5.4. Radiographic Tests
5.4.1. Chest X-rays
5.4.2. Computed Tomography
5.5. Molecular Tests
5.5.1. Rapid Diagnostic Tests
5.5.2. Whole Genome Sequencing
5.5.3. Nucleic Acid Amplification Test
5.5.4. Other Molecular Tests
5.6. Sputum Smear Microscopy
5.7. Culture & Drug Resistance
5.8. Other Test Types
6. Tuberculosis Diagnostics Market Assessment—by Infection Stage
6.1. Overview
6.2. Active
6.3. Latent
7. Tuberculosis Diagnostics Market Assessment—by End User
7.1. Overview
7.2. Diagnostic Laboratories
7.3. Hospitals & Clinics
7.4. Academic & Research Institutes
7.5. Other End Users
8. Tuberculosis Diagnostics Market Assessment—by Geography
8.1. Overview
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. U.K.
8.3.4. Italy
8.3.5. Spain
8.3.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. China
8.4.2. India
8.4.3. Japan
8.4.4. Indonesia
8.4.5. Thailand
8.4.6. Philippines
8.4.7. South Korea
8.4.8. Singapore
8.4.9. Australia
8.4.10. Rest of Asia-Pacific
8.5. Latin America
8.6. Middle East
8.7. Africa
8.7.1. South Africa
8.7.2. Nigeria
8.7.3. Kenya
8.7.4. Rest of Africa
9. Competition Analysis
9.1. Overview
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
9.4. Competitive Dashboard
9.4.1. Industry Leaders
9.4.2. Market Differentiators
9.4.3. Vanguards
9.4.4. Emerging Companies
9.5. Market Share Analysis/Market Ranking, by Key Players (2023)
10. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)
10.1. F. Hoffmann-La Roche Ltd.
10.2. Becton, Dickinson and Company
10.3. Abbott Laboratories, Inc.
10.4. Thermo Fisher Scientific, Inc.
10.5. QIAGEN GmbH
10.6. Hologic, Inc.
10.7. bioMérieux SA (France)
10.8. Danaher Corporation
10.9 Oxford Immunotec Ltd. (U.K.)
10.10. Hain Lifescience GmbH
10.11. Creative Diagnostics
(Note: SWOT analysis of the top 5 companies will be provided)
11. Appendix
11.1. Available Customization
11.2. Related Reports
List of Tables
Table 1 Global Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 2 Global Tuberculosis Skin Test Market, by Country/Region, 2022–2031 (USD Million)
Table 3 Global Tuberculosis Interferon Gamma Release Assay Market, by Country/Region, 2022–2031 (USD Million)
Table 4 Global Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 5 Global Tuberculosis Chest X-ray Market, by Country/Region, 2022–2031 (USD Million)
Table 6 Global Tuberculosis Computed Tomography Market, by Country/Region, 2022–2031 (USD Million)
Table 7 Global Molecular Tests Market for Tuberculosis, by Country/Region, 2022–2031 (USD Million)
Table 8 Global Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 9 Global Rapid Diagnostic Tests Market for Tuberculosis, by Country/Region, 2022–2031 (USD Million)
Table 10 Global Whole-genome Sequencing Market for Tuberculosis, by Country/Region, 2022–2031 (USD Million)
Table 11 Global Nucleic Acid Amplification Test Market for Tuberculosis, by Country/Region, 2022–2031 (USD Million)
Table 12 Global Other Molecular Tests Market for Tuberculosis, by Country/Region, 2022–2031 (USD Million)
Table 13 Global Sputum Smear Microscopy Market for Tuberculosis, by Country/Region, 2022–2031 (USD Million)
Table 14 Global Culture & Drug Resistance Market for Tuberculosis, by Country/Region, 2022–2031 (USD Million)
Table 15 Global Other Test Types Market for Tuberculosis, by Country/Region, 2022–2031 (USD Million)
Table 16 Global Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 17 Global Active Tuberculosis Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 18 Global Latent Tuberculosis Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 19 Global Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 20 Global Tuberculosis Diagnostics Market for Diagnostic Laboratories, by Country/Region, 2022–2031 (USD Million)
Table 21 Global Tuberculosis Diagnostics Market for Hospitals & Clinics, by Country/Region, 2022–2031 (USD Million)
Table 22 Global Tuberculosis Diagnostics Market for Academic & Research Institutes, by Country/Region, 2022–2031 (USD Million)
Table 23 Global Contract Manufacturing Market for Other End Users, by Country/Region, 2022–2031 (USD Million)
Table 24 Global Tuberculosis Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 25 North America: Tuberculosis Diagnostics Market, by Country, 2022–2031 (USD Million)
Table 26 North America: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 27 North America: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 28 North America: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 29 North America: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 30 North America: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 31 U.S.: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 32 U.S.: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 33 U.S.: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 34 U.S.: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 35 U.S.: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 36 Canada: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 37 Canada: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 38 Canada: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 39 Canada: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 40 Canada: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 41 Europe: Tuberculosis Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 42 Europe: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 43 Europe: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 44 Europe: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 45 Europe: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 46 Europe: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 47 Germany: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 48 Germany: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 49 Germany: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 50 Germany: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 51 Germany: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 52 France: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 53 France: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 54 France: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 55 France: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 56 France: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 57 U.K.: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 58 U.K.: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 59 U.K.: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 60 U.K.: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 61 U.K.: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 62 Italy: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 63 Italy: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 64 Italy: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 65 Italy: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 66 Italy: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 67 Spain: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 68 Spain: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 69 Spain: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 70 Spain: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 71 Spain: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 72 Rest of Europe: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 73 Rest of Europe: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 74 Rest of Europe: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 75 Rest of Europe: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 76 Rest of Europe: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 77 Asia-Pacific: Tuberculosis Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 78 Asia-Pacific: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 79 Asia-Pacific: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 80 Asia-Pacific: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 81 Asia-Pacific: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 82 Asia-Pacific: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 83 China: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 84 China: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 85 China: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 86 China: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 87 China: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 88 India: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 89 India: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 90 India: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 91 India: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 92 India: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 93 Japan: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 94 Japan: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 95 Japan: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 96 Japan: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 97 Japan: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 98 Indonesia: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 99 Indonesia: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 100 Indonesia: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 101 Indonesia: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 102 Indonesia: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 103 Thailand: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 104 Thailand: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 105 Thailand: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 106 Thailand: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 107 Thailand: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 108 Philippines: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 109 Philippines: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 110 Philippines: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 111 Philippines: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 112 Philippines: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 113 South Korea: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 114 South Korea: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 115 South Korea: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 116 South Korea: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 117 South Korea: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 118 Singapore: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 119 Singapore: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 120 Singapore: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 121 Singapore: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 122 Singapore: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 123 Australia: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 124 Australia: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 125 Australia: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 126 Australia: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 127 Australia: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 128 Rest of Asia-Pacific: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 129 Rest of Asia-Pacific: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 130 Rest of Asia-Pacific: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 131 Rest of Asia-Pacific: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 132 Rest of Asia-Pacific: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 133 Latin America: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 134 Latin America: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 135 Latin America: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 136 Latin America: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 137 Latin America: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 138 Middle East: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 139 Middle East: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 140 Middle East: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 141 Middle East: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 142 Middle East: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 143 Africa: Tuberculosis Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 144 Africa: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 145 Africa: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 146 Africa: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 147 Africa: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 148 Africa: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 149 South Africa: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 150 South Africa: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 151 South Africa: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 152 South Africa: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 153 South Africa: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 154 Nigeria: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 155 Nigeria: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 156 Nigeria: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 157 Nigeria: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 158 Nigeria: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 159 Kenya: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 160 Kenya: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 161 Kenya: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 162 Kenya: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 163 Kenya: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 164 Rest of Africa: Tuberculosis Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Table 165 Rest of Africa: Tuberculosis Radiographic Tests Market, by Type, 2022–2031 (USD Million)
Table 166 Rest of Africa: Molecular Tests Market for Tuberculosis, by Type, 2022–2031 (USD Million)
Table 167 Rest of Africa: Tuberculosis Diagnostics Market, by Infection Stage, 2022–2031 (USD Million)
Table 168 Rest of Africa: Tuberculosis Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 169 Recent Developments, by Company, 2021-2023
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Global Tuberculosis Diagnostics Market, by Test Type, 2024 Vs.2031 (USD Million)
Figure 8 Global Tuberculosis Diagnostics Market, by Infection Stage, 2024 Vs.2031 (USD Million)
Figure 9 Global Tuberculosis Diagnostics Market, by End User, 2024 Vs.2031 (USD Million)
Figure 10 Global Tuberculosis Diagnostics Market, by Geography
Figure 11 Impact Analysis of Market Dynamics
Figure 12 Global Tuberculosis Diagnostics Market, by Test Type, 2024 Vs.2031 (USD Million)
Figure 13 Global Tuberculosis Diagnostics Market, by Infection Stage, 2024 Vs.2031 (USD Million)
Figure 14 Global Tuberculosis Diagnostics Market, by End User, 2024 Vs.2031 (USD Million)
Figure 15 North America: Tuberculosis Diagnostics Market Snapshot
Figure 16 Europe: Tuberculosis Diagnostics Market Snapshot
Figure 17 Asia-Pacific: Tuberculosis Diagnostics Market Snapshot
Figure 18 Africa: Tuberculosis Diagnostics Market Snapshot
Figure 19 Key Growth Strategies Adopted by Leading Players (2021–2024)
Figure 20 Tuberculosis Diagnostics Market: Competitive Benchmarking, by Application
Figure 21 Tuberculosis Diagnostics Market: Competitive Benchmarking, by Region
Figure 22 Competitive Dashboard Tuberculosis Diagnostics Market
Figure 23 Global Tuberculosis Diagnostics Market Share/Market Ranking Analysis, by Key Players, 2023
Figure 24 F. Hoffmann-La Roche Ltd..: Financial Overview (2023)
Figure 25 Becton, Dickinson and Company.: Financial Overview (2023)
Figure 26 Abbott Laboratories, Inc.: Financial Overview (2023)
Figure 27 Thermo Fisher Scientific, Inc.: Financial Overview (2023)
Figure 28 QIAGEN GmbH: Financial Overview (2023)
Figure 29 Hologic, Inc.: Financial Overview (2023)
Figure 30 bioMérieux SA: Financial Overview (2023)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Europe Molecular Diagnostics Market - Opportunity Analysis and Industry Forecast (2024 -2030)
Published Date: Jul-2024
Livestock Diagnostics Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: May-2024
Europe Cancer Diagnostics Market- Opportunity Analysis And Industry Forecast (2024-2031)
Published Date: Feb-2024
Latin America Molecular Diagnostics Market - Opportunity Analysis and Industry Forecasts (2024-2031)
Published Date: Jan-2024
Europe Livestock Diagnostics Market - Opportunity Analysis and Industry Forecasts (2024-2031)
Published Date: Jan-2024
